Introduction: Sickle cell anemia is a disease characterized by a wide vaso-occlusive incident from micro-vascular incident to muscularactivity. The cochlear function can also get affected by this vaso-occlusion. Objective: It is aimed at determining what kind of effects sickle cell anemia has on hearing and balance system. Methods: This study has been conducted on 46 patients with sickle cell anemia and 45 healthy individuals. For all participants, their pure tone hearing thresholds and videonystagmography (VNG) findings have been determined in 17 frequencies between 125–16.000 Hz. Results: All hearing thresholds between 125 and 16,000 Hz, pure tone averages of patients with sickle cell anemia have been found statistically significant to be higher than the corresponding values in the control group(p < 0.05). The normal hearing rate of patients with sickle cell anemia has been determined to be 71.1% conductive hearing loss (CHL) to be 4.4%, sensorineural hearing loss (SNHL) to be 22.2%, and mixed type hearing loss to be 2.2% in right ear; the normal hearing rate has been determined to be 71.1%, CHL to be 2.2%, SNHL to be 22.2%, and mixed type hearing loss to be 4.4% in left ear. Statistically significant difference has not been found between head shake, spontaneous nystagmus, optokinetic, tracking test batteries, static and dynamic positional tests used in VNG, saccade accuracy and saccade peak velocity, which are saccadic test findings of 2 groups. However, saccadic latency, which is a saccadic test finding, has been determined to be longer in patients with sickle cell anemia in comparison to the control group. Conclusion: While sickle cell anemia causes hearing deficits, it does not have any effect on the central or peripheral vestibular system.

Keywords:
Sickle cell anemia, Hearing loss, Vertigo, Audiometry
1.
Burch Sims GP, Matlock VR: Hearing loss and auditory function in sickle cell disease. J Commun Disord 2005; 38: 321–329.
2.
Downs Renee C, Stuart A: Distortion product otoacoustic emission in normal hearing children with homozygous sickle cell disease. J Commun Disord 2000; 33: 111–129.
3.
Saito N, Watanabe M, Liao J, Flower EN, Nadgir RN, Steinberg MH, et al: Clinical and radiologic findings of inner ear involvement in sickle cell disease. AJNR Am J Neuroradiol 201; 132: 2160–2164.
4.
Taipalee A, PelkonenT, Bernardino L, Peltola H, Pitkaranta A: Hearing loss in Angolan children with sickle cell disease. Pediatr Int 2012; 54: 854–857.
5.
Mace AD, Ferguson MS, Offer M, Ghufoor K, Wareing M.J: Bilateral profound sudden sensorineural hearing loss presenting a diagnostic conundrum in a child with sickle cell anaemia. J Laryngol Otol 2009; 123: 811–816.
6.
Stuart A, Preast JL: Contralateral suppression of transient-evoked otoacoustic emissions in children with sickle cell disease. Ear Hear 2012; 33: 421–429.
7.
Kamal E, Elhamd A: Otorhinolaryngological manifestations of sickle cell disease. Int J Pediatr Otorhinolaryngol 2012; 76: 1–4.
8.
Mgbor N, Ifeoma E: Sensorineural hearing loss in nigerian children with sickle cell disease. Int J Pediatr Otorhinolaryngol 2004; 68: 1413–1416.
9.
LiuB.P, Saito N, Wang JJ, Mian AZ, Sakai O: Labyrinthitis ossificans in a child with sickle cell disease: CT and MRI Findings. Pediatr Radiol 2009; 39: 999–1001.
10.
Belliard RC, Lesprit E, Quinet B, Vacher W S, Saizou C, Grimprel E: Vestibular neuronitis in a teenager with sickle cell disease. Treatment is urgent. Arch Pediatr 2008; 15: 1423–1425.
11.
Clark JG: Uses and abuses of hearing loss classification. Asha 1981; 23: 493–500.
12.
Okbi MH, Alkindi S, Abri RK., Mathew J, Nagwa A, Pathare AV: Sensorineural hearing loss in sickle cell disease. Laryngoscope 2011; 121: 392–396.
13.
Onakoya PA, Nwaorgu OG, Shokunbi WA: Sensorineural hearing loss in adults with sickle cell anaemia. Afr J Med Med Sci 2002; 31: 21–24.
14.
Forman-Franco B, Karayalan G, Mandel DD, Abramson AL: The evaluation of auditory function in homozygous sickle cell disease. Otolaryngol Head Neck Surg 1982; 90: 850–856.
15.
Alabi S, Kolade E, Paul E, Adesina O, Abdul A: Otological findings among Nigerian children with sickle cell anaemia. Int J Pediatr Otorhinolaryngol 2008; 72: 659–663.
16.
Stuart MJ, Nagel RL: Sickle cell disease. Lancet 2004; 364: 1343–1360.
17.
Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl 2002; 548: 38–43.
18.
Odetoyinbo O, Adekile A: Sensorineural hearing loss in children with sickle cell anemia, Ann Otol Rhinol Laryngol 1987; 96: 258–260.
19.
Ogisi FO, Okafor LA: Assessment of auditory function in sickle cell anemia patients in Nigeria. Trop Geogr Med 1987; 39: 28–31.
20.
Atsina K, Ankra-Badu G: Sensorineural hearing loss in Ghanaians with sickle cell anaemia. Trop Geogr Med 1988; 40: 204–208.
21.
Tsibuleyskaya G, Oburra H, Aluoch J: Sensorineural hearing loss in patients with sickle cell anaemia in Kenya. East Afr Med J 1996; 73: 471–473.
22.
Silva IM, Magalhaes I, Toscano RA, Gandolfi L, Pratesi R: Auditory evoked response analysis in Brazilian patients with sickle cell disease. Int J Audiol 2010; 49: 272–276.
23.
Abel LA, Troost BT, Dell’Osso F: The effects of age on normal saccadic characteristics and their variability. Vision Res 1983; 23: 33–37.
24.
Bedell HE, Stevenson SB: Eye movement testing in clinical examination. Vision Res 2013; 90: 33–37.
25.
Todd G, Sergeant G, Larson M: Sensorineural hearing loss in Jamaicans with sickle cell disease, Acta Otolaryngol 1973; 76: 268–272.
26.
Chollet O, BricheT, Diard JP: Sickle cell disease and vertigo: a possible diagnosis in metropolitan France. Review of the literatüre and case report. Med Trop 2002; 62: 525–530.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.